Benefit With Impella?  by Garratt, Kirk N. & Holmes, David R.
B
W
w
I
i
o
p
d
w
p
s
f
8
e
a
o
(
P
S
r
n
h
I
4
o
I
r
s
u
d
d
P
t
I
H
i
c
*
D
*
1
9
N
E
Journal of the American College of Cardiology Vol. 55, No. 23, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
R
1
2
3
R
W
(
I
m
i
a
c
E
m
q
I
a
r
c
S
w
P
E
i
i
m
o
d
e
d
a
p
l
w
d
p
v
d
“
n
t
Penefit With Impella?
e are concerned about the report from the Europella registry (1),
hich described the use of the Impella 2.5 device (ABIOMED
nc., Danvers, Massachusetts) in 144 European patients undergo-
ng elective high-risk coronary intervention. If this device or any
ther has merit in an elective, high-risk population, it must
roduce fewer adverse events than would be expected without the
evice.
Most patients had multivessel disease; left main disease (LMD)
as listed as a high-risk criterion for more than one-half of the
atients. Reported 30-day mortality figures were 5.5% overall, with
urprisingly little variation as a function of left ventricular ejection
raction. Mortality rates were much higher among LMD patients:
.3% overall, and 12% for those with LMD and low left ventricular
jection fraction.
The mean EuroSCORE (European System for Cardiac Oper-
tive Risk Evaluation) of about 8 suggests a 30-day mortality risk
f about 5% with unsupported percutaneous coronary intervention
2). The investigators note that in the SYNTAX (Synergy between
ercutaneous Coronary Intervention with Taxus and Cardiac
urgery) trial (3), 12-month mortality was 7.3% for patients who
efused bypass surgery, but the 30-day risk for such patients was
ot reported in SYNTAX, and surgical turn-down was cited as a
igh-risk feature in fewer than one-half of the patients in the
mpella registry. Overall 12-month mortality in SYNTAX was
.3%, and for LMD patients it was 4.2%, which is roughly
ne-half the 30-day mortality for LMD patients treated with
mpella in this registry. This is of concern as an overall mortality
isk that matches or exceeds the risk predicted without special
upport and questions the magnitude of benefit achieved through
se of Impella. Ease of use is an attractive feature of the Impella
evice, but ease should not drive its use in the absence of
emonstrated efficacy. We anxiously await the completion of
ROTECT II (A Prospective Multicenter, Randomized Con-
rolled Trial of the Impella Recover LP 2.5 System versus
ntra-Aortic Balloon Pump in Patients Undergoing Nonemergent
igh-Risk PCI) trial, which will clarify possible benefits of this
ntermediate support device in elective high-risk percutaneous
oronary intervention.
Kirk N. Garratt, MSc, MD
avid R. Holmes, MD
Lenox Hill Hospital
30 East 77th Street
th Floor, Black Hall
ew York, New York 10075
-mail: kgarratt@lenoxhill.netdoi:10.1016/j.jacc.2010.02.038 rEFERENCES
. Sjauw K, Konorza T, Erbel R, et al. Supported high-risk percutaneous
coronary intervention with the Impella 2.5 device. The Europella
registry. J Am Coll Cardiol 2009;54:2430–4.
. Romagnoli E, Burzotta F, Trani C. EuroSCORE as predictor of
in-hospital mortality after percutaneous coronary intervention. Heart
2009;95:43–8.
. Serruys P, Morice MC, Kappetein AP, et al., on behalf of SYNTAX
Investigators. Percutaneous coronary intervention versus coronary-
artery bypass grafting for severe coronary artery disease. N Engl J Med
2009;360:961–72.
eply
e thank Drs. Garratt and Holmes for their interest in our report
1), and we could not agree more with their statement that the
mpella 2.5 or any other mechanical cardiac-assist device only has
erit in the setting of elective high-risk percutaneous coronary
ntervention (PCI) if there are more benefits than iatrogenic
dverse events to expect. However, we do not agree with the raised
oncerns with regard to the 30-day mortality rate of 5.5% in the
uropella registry (1).
Drs. Garratt and Holmes state that an overall mortality risk that
atches or exceeds the risk predicted without special support
uestions the magnitude of benefit achieved through use of
mpella. However, the mortality rates mentioned by Drs. Garratt
nd Holmes are far from comparable with the mortality rate
eported in the Europella registry. First, the deduction from the
ited study of Romagnoli et al. (2) that a EuroSCORE (European
ystem for Cardiac Operative Risk Evaluation) of 8 corresponds
ith a 30-day mortality risk of about 5% in unsupported elective
CI is invalid. This single-center study only shows that the
uroSCORE has good discriminative power to predict mortality
n the included cohort of PCI patients. Only if both studies had
ncluded approximately similar patients, a crude comparison of
ortality rates would have been reasonable. However, the case mix
f patients in the study of Romagnoli et al. (2) was completely
ifferent than the Europella registry (e.g., both emergent and
lective patients; lower age; considerably lower frequencies of
iabetes, hypertension, renal failure, peripheral vascular disease,
nd stroke; normal left ventricular ejection fraction in 75% of
atients; and only 2.3% had left main disease). Moreover, due to
ack of angiographic parameters of coronary anatomy, patients
ith identical “surgical” EuroSCOREs may have completely
ifferent mortality rates.
The Europella registry included a selected group of high-risk
atients from multiple centers with high morbidity, poor left
entricular ejection fraction, and complex 3-vessel and left main
isease seldom included in previous trials. Therefore, as part of the
real-world” design of the SYNTAX (Synergy between Percuta-
eous Coronary Intervention with Taxus and Cardiac Surgery)
rial (3) (eligibility for coronary artery bypass graft [CABG] or
CI judged in the “Heart-Team Conference”), the SYNTAX
egistry for CABG ineligible patients in our opinion included the
